Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy
Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy
复制标题
DOI：
10.1016/j.bcmd.2006.06.003
复制
发表时间：
2006-09-01
影响因子：
2.3
通讯作者：
Acton, R. T.
中科院分区：
文献类型：
--
作者：
Limdi, N. A.;Beasley, T. M.;Acton, R. T.
我们报告的患病率因子V莱顿（FVL）在欧洲裔美国人和非洲裔美国人的华法林治疗居住在亚拉巴马患者。方法：获得详细的历史和FVL基因型确定288例患者参加了前瞻性队列：抗凝治疗的药物遗传学优化。基因型频率的种族差异通过卡方统计和HWE假设通过G统计进行评估。种族特异性分析血栓栓塞和存在FVL突变的网站之间的关联进行了评估使用logistic regression.Results：总杂合子（GA基因型）的频率为4.9%。没有发现患者为变异等位基因纯合子（AA）。与非洲裔美国人（1.4%）患者相比，欧洲裔美国人（8.6%）的GA患病率更高（p=0.004）。不同种族间静脉血栓栓塞事件的FVL基因型频率有显著差异（p=0.014），但动脉血栓栓塞事件的FVL基因型频率无显著差异（p=0.20）。多变量种族特异性分析强调了FVL突变对欧洲裔美国人（p=0.03）而非非洲裔美国人患者（p=0.95）静脉血栓栓塞事件风险的贡献。与GA突变的欧洲裔美国人患者约6.3倍更有可能经历了静脉，而不是动脉血栓栓塞events.Conclusion：在亚拉巴马，华法林患者中，GA基因型是更普遍的欧洲裔美国人相比，非洲裔美国人。在欧洲裔美国人中，而不是在非洲裔美国人中，GA基因型在静脉血栓栓塞事件患者中比动脉血栓栓塞事件患者更普遍。(c)2006年爱思唯尔公司All rights reserved.
We report the prevalence of Factor V Leiden (FVL) in European American and African American patients on warfarin therapy residing in Alabama.Methods: Detailed history was obtained and FVL genotype was determined for 288 patients enrolled in a prospective cohort: Pharmacogenetic Optimization of Anticoagulation Therapy. Racial differences in genotype frequency were assessed by the Chi-square statistics and HWE assumptions by G-statistics. Race-specific analysis for the association between site of thromboembolism and the presence of FVL mutation was assessed using logistic regression.Results: The overall heterozygote (GA genotype) frequency was 4.9%. No patient was found to be homozygous (AA) for the variant allele. The prevalence of GA was higher in European American (8.6%) compared to African American (1.4%) patients (p=0.004). The FVL genotype frequency was significantly different across race for venous thromboembolic events (p=0.014) but not for arterial thromboembolic events (p=0.20). Multivariable race-specific analysis highlights the contribution of FVL mutation to the risk of venous thromboembolic events in European American (p=0.03) but not in African American patients (p=0.95). European American patients with the GA mutation were approximately 6.3 times more likely to have experienced a venous, rather than arterial thromboembolic event.Conclusion: In Alabama, among patients on warfarin, the GA genotype is more prevalent in European Americans compared to African Americans. In European Americans, but not in African Americans, the GA genotype was more prevalent in patients with venous compared to arterial thromboembolic events. (c) 2006 Elsevier Inc. All rights reserved.